{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:38:28Z","timestamp":1787168308537,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB29010205"],"award-info":[{"award-number":["XDB29010205"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31670172"],"award-info":[{"award-number":["31670172"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"973 Program","doi-asserted-by":"publisher","award":["2015CB554300"],"award-info":[{"award-number":["2015CB554300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","award":["2017ZX09101-005-001-005"],"award-info":[{"award-number":["2017ZX09101-005-001-005"]}],"id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.antiviral.2019.104612","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T11:11:49Z","timestamp":1568891509000},"page":"104612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness"],"prefix":"10.1016","volume":"171","author":[{"given":"Mingzhe","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104612_bib1","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104612_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx009","article-title":"Pediatric drug nitazoxanide: a potential choice for control of zika","volume":"4","author":"Cao","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104612_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40265-016-0685-x","article-title":"Genotype 3 infection: the last stand of hepatitis C virus","volume":"77","author":"Chan","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2019.104612_bib4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2174\/1389557517666170913111930","article-title":"Recent advancement of direct-acting antiviral agents (DAAs) in hepatitis C therapy","volume":"18","author":"Das","year":"2018","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.104612_bib5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104612_bib6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104612_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coph.2016.07.014","article-title":"HCV NS5A replication complex inhibitors","volume":"30","author":"Gao","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.104612_bib8","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1128\/JVI.02667-09","article-title":"Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies","volume":"84","author":"Gottwein","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104612_bib9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.gastro.2011.06.004","article-title":"Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3\/4A protease recombinant viruses","volume":"141","author":"Gottwein","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104612_bib10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/jvi.67.3.1385-1395.1993","article-title":"Expression and identification of hepatitis C virus polyprotein cleavage products","volume":"67","author":"Grakoui","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104612_bib11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104612_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/hep.30647","article-title":"Evolutionary pathways to persistence of highly fit and resistant hepatitis C virus protease inhibitor escape variants","volume":"70","author":"Jensen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104612_bib13","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1128\/AAC.01953-15","article-title":"Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance","volume":"59","author":"Jensen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104612_bib14","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1053\/j.gastro.2003.09.023","article-title":"Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon","volume":"125","author":"Kato","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104612_bib15","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1128\/JVI.02334-06","article-title":"Production of infectious hepatitis C virus of various genotypes in cell cultures","volume":"81","author":"Kato","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104612_bib16","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1128\/JVI.75.10.4614-4624.2001","article-title":"Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations","volume":"75","author":"Krieger","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104612_bib17","article-title":"Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104612_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.virol.2018.03.001","article-title":"Identification of nucleotides in the 5'UTR and amino acids substitutions that are essential for the infectivity of 5'UTR-NS5A recombinant of hepatitis C virus genotype 1b (strain Con1)","volume":"518","author":"Li","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104612_bib19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104612_bib20","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.bmcl.2019.04.027","article-title":"Discovery of velpatasvir (GS-5816): a potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi((R)) and Epclusa((R))","volume":"29","author":"Link","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.104612_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104612_bib22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104612_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2013.04.030","article-title":"Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates","volume":"443","author":"Lu","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104612_bib24","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/JVI.02929-13","article-title":"A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate","volume":"88","author":"Lu","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104612_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104612_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2893.2011.01451.x","article-title":"Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus","volume":"18","author":"Morikawa","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2019.104612_bib27","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1111\/j.1365-2893.2011.01441.x","article-title":"HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis","volume":"18","author":"Nkontchou","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2019.104612_bib28","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104612_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2893.2011.01481.x","article-title":"Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis","volume":"18","author":"Probst","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2019.104612_bib30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104612_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.104612_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature14899","article-title":"SEC14L2 enables pan-genotype HCV replication in cell culture","volume":"524","author":"Saeed","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.104612_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.gastro.2012.09.017","article-title":"Replication of hepatitis C virus genotype 3a in cultured cells","volume":"144","author":"Saeed","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104612_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104612_bib35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s12072-016-9733-6","article-title":"Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis","volume":"10","author":"Shrivastava","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2019.104612_bib36","doi-asserted-by":"crossref","first-page":"11850","DOI":"10.1021\/jacs.6b06454","article-title":"Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3\/4a protease","volume":"138","author":"Soumana","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2019.104612_bib37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jhep.2018.08.029","article-title":"Sofosbuvir\/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: response to EASL Recommendations on Treatment of Hepatitis C 2018","volume":"70","author":"Stamm","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104612_bib38","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104612_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.antiviral.2016.12.009","article-title":"A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals","volume":"139","author":"Tao","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104612_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virol.2009.09.006","article-title":"A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles","volume":"395","author":"Tao","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104612_bib41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2019.104612_bib42","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.gastro.2019.05.007","article-title":"Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir","volume":"157","author":"Wing","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104612_bib43","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219304693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219304693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:30:18Z","timestamp":1759062618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219304693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":43,"alternative-id":["S0166354219304693"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104612","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104612"}}